ASCO 2026: Immatics is presenting data on its second generation PRAME targeting cell therapy in gynecological cancers and synovial sarcoma
- May 30
- 1 min read
CEO Harpreet Singh walks us though the data and reminds us how this second generation approach uses CD4+ helper T-cells in addition to CD8 for additional firepower.










.png)